Glioblastoma is the most aggressive primary brain cancer, with a median survival of 1 to 2 years 1 . These tumours contain glioma stem cells (GSCs), which are highly tumorigenic, resistant to conventional therapies 2,3 , and exhibit metabolic plasticity to adapt to challenging environments 4,5 . GSCs can be specifically targeted by a short cell-penetrating peptide based on connexin43 (Cx43) (TAT-Cx43266-283) that reduces tumour growth and increases survival in preclinical models 6 via c-Src inhibition 7 . Because several reports revealed poor clinical efficacy of various antitumoral drugs due to metabolic rewiring in cancer cells 8-10 , we investigated the effect of TAT-Cx43266-283 on GSC metabolism and metabolic plasticity. Here we show that TAT-Cx43266-283 decreases GSC glucose uptake and oxidative phosphorylation without a compensatory increase in glycolysis, with no effect on neuron or astrocyte metabolism. GSC changes were mediated by decreased hexokinase (HK) activity and aberrant mitochondrial localization, ultrastructure and function. Moreover, TAT-Cx43266-283 reduced GSC growth and survival under different nutrient availability conditions by impairing the metabolic plasticity needed to exploit glucose as an energy source in the absence of other nutrients. Finally, GSCs intracranially implanted into mice together with TAT-Cx43266-283 showed decreased levels of important targets for cancer therapy, such as HK-2 11,12 and glucose transporter 3 (GLUT-3) 13 , evidencing the reduced ability of treated GSCs to survive in challenging environments. Our results confirm the value of TAT-Cx43266-283 for glioma therapy alone or in combination with therapies whose resistance relies on metabolic adaptation. More importantly,
these results allow us to conclude that the advantageous metabolic plasticity of GSCs is a targetable vulnerability in malignant gliomas.
Introduction
Glioblastoma (World Health Organization grade IV glioma) is the most common and aggressive primary brain cancer, with a median survival of 16 months 1 . A subset of cells within these tumours, termed glioma stem cells (GSCs), display highly tumorigenic capacity and resistance to conventional therapies, and are therefore considered responsible for recurrence 2, 3 . The GSC phenotype is dynamic and can be acquired by non-GSCs upon challenging conditions, suggesting that inherent cancer cell plasticity is a relevant target for treatment 13, 14 . These challenging conditions, which include hypoxia, an acidic environment or metabolic stress, promote the enrichment of the highly tumorigenic GSC population 13, 15, 16 . In this regard, an important feature of cancer stem cells, and particularly of GSCs, is their metabolic plasticity, which allows them to survive nutrient deprivation by conveniently shifting between different metabolic pathways used in energy production and catabolism 4, 5, [17] [18] [19] . In particular, glucose metabolism plays a key role in glioma, as glucose restriction promotes GSC enrichment through a two-fold mechanism: direct selection of GSCs, because they have the metabolic phenotype required to survive in this environment, and adaptation of some non-GSCs through the acquisition of GSC metabolic features 13 . One of these GSC features is elevated expression of the high affinity glucose transporter, GLUT-3, which is crucial for tumorigenicity of GSCs, and consequently, for progression and malignancy of human gliomas 13 .
Characteristically, glioma cells, including GSCs, express low levels of connexin43 (Cx43), as opposed to astrocytes, one of their healthy counterparts 7, 20, 21 . In addition to forming intercellular gap junctions, Cx43 has gathered plenty of attention in recent years for its C-terminal domain 22 , which interacts with a plethora of molecules and acts as an intracellular signaling hub 23 . This is the case of the proto-oncoprotein c-Src, which is recruited by Cx43 together with its inhibitors CSK and PTEN 24 , causing the inhibition of c-Src and its oncogenic downstream pathways 25 . Based on this inhibitory mechanism, we designed a cell-penetrating peptide, TAT-Cx43266-283, containing the region of Cx43 required for the inhibition of c-Src 7 . Importantly, TAT-Cx43266-283 exerts potent antitumor effects on glioma cells 26 , including the reversion of GSC phenotype 7 in vitro and in vivo without affecting healthy brain cells 6 .
The relationship between the oncogenic activity of c-Src and glucose metabolism was first described in 1985 27 . Since then, many studies have delved into the underlying mechanisms. c-Src can modulate glucose metabolism either indirectly through master transcription factors, such as c-myc 28 or hypoxia inducible factor 1ɑ (HIF-1ɑ) 29, 30 , or directly through the regulation of the activity of key glucose metabolism proteins, such as HK-2 12 , which traps glucose intracellularly for further metabolization, or glucose-6-phosphate-dehydrogenase (G6PD) 31 , the key and rate-limiting enzyme in the pentose phosphate pathway.
In addition to a conferred advantage to survive in nutrient-deprived conditions, metabolic plasticity is responsible for resistance to certain cancer treatments, one of the most relevant hallmarks of GSCs 2,3 . For example, glioma cells adapt to bevacizumab treatment -a common antiangiogenic therapy -by increasing glycolisis 8, 32 . Similarly, tumour cells can rewire their metabolism to suit their needs under different environment conditions, which can negatively affect their response to common antitumoral drugs, such as mTOR 9 and glutaminase inhibitors 33 , 5-fluorouracil and metformin, and even to immunotherapy 10 .
Consequently, the inhibition of this metabolic plasticity is becoming a promising therapeutic target, and its cell selectivity is undoubtedly hugely important in the context of brain tumours. Therefore, here we investigated the effect of TAT-Cx43266-283, a promising therapeutic peptide against glioma, on GSC metabolism and metabolic plasticity as a meaningful predictor of the success of a future clinical application.
Results

TAT-Cx43266-283 decreases glucose uptake selectively in GSCs
Because the highly efficient glucose uptake in GSCs confers these cells with a competitive advantage within the brain environment 13 , we first analysed the effect of TAT-Cx43266-283 on glucose transport and uptake in GSCs, neurons and astrocytes. Glucose transport was evaluated in GSCs using the nonmetabolizable fluorescent glucose analogue 6-NBDG, whose uptake reflects gradient-driven influx through glucose transporters 34 . We found no differences in 6-NBDG transport (146 μM for 1 h) between controls (untreated condition (Control) and negative control (TAT)) and TAT-Cx43266-283-treated GSCs (50 μM, 24 h), suggesting that TAT-Cx43266-283 does not modify glucose transport under these experimental conditions (Fig. 1a ).
To confirm this result, we analysed GLUT-1, the main glucose transporter.
GLUT-1 levels in GSCs were not affected by TAT-Cx43266-283 treatment ( Fig. 1b and c and Supplementary Fig. 1a and b ). However, the complexity of the GLUT-1 staining pattern in the cell membrane decreased after TAT-Cx43266-283 treatment ( Fig. 1b , inset). To quantify this finding, the fractal dimension of the GLUT-1 images was calculated as an index of membrane complexity (see Methods). The lower values obtained for the TAT-Cx43266-283 images suggest that TAT-Cx43266-283 decreases the complexity of membrane GLUT-1 staining in GSCs ( Fig. 1d ). This might be due to changes in the polymerization state of the actin cytoskeleton caused by TAT-Cx43266-283 35 , which can modulate GLUT-1 clustering without affecting glucose transport 36 . The levels of GLUT-3, another glucose transporter frequently co-opted by cancer cells 13 , were not affected by TAT-Cx43266-283 under these experimental conditions ( Fig. 1c ).
Next, we measured glucose uptake with the non-metabolizable fluorescent glucose analogue 2-NBDG, which is phosphorylated by HK and trapped intracellularly. The results showed that TAT-Cx43266-283 decreased glucose uptake in GSCs by ~30%, whereas uptake was unchanged in neurons and astrocytes ( Fig. 1e and f ). This result adds to the evidence from our previous report that TAT-Cx43266-283 specifically targets GSCs 6 . Moreover, TAT-Cx43266-283 reduced HK activity ( Fig. 1g ) without altering the levels of HK-1 and HK-2 in GSCs treated with TAT-Cx43266-283 ( Fig. 1c and Supplementary Fig. 1c ). Because HK-1 and HK-2 activity is upregulated by c-Src phosphorylation 12 , the TAT-Cx43266-283-induced inhibition of c-Src 7,26 might hinder HK activity.
Immunofluorescence assays revealed that both HKs localized more compactly around the nuclei of GSCs treated with TAT-Cx43266-283 ( Fig. 1h ). Taken together, these data indicate that 24-h treatment with TAT-Cx43266-283 reduces glucose uptake selectively in GSCs through decreased HK activity, without affecting glucose transport or the protein levels of GLUT-1, GLUT-3, HK-1 or HK-2.
TAT-Cx43266-283 reduces mitochondrial metabolism without increasing glycolysis in GSCs
Because we found that TAT-Cx43266-283 altered the location of HKs (Fig. 1h ), which are frequently associated with mitochondria 11, 12 , we used a mitochondrial dye to follow the cellular distribution of these organelles. Importantly, these images revealed that TAT-Cx43266-283 treatment (50 μM, 24 h) modified the localization of mitochondria in GSCs but not in astrocytes ( Fig. 2a and Supplementary Fig. 2a ). Indeed, the distance from the furthest mitochondria to the nucleus was reduced in GSCs after TAT-Cx43266-283 treatment ( Fig. 2b ), suggesting altered mitochondrial trafficking. This change in mitochondrial localization might arise from cytoskeleton rearrangement 35 and contribute to the reported TAT-Cx43266-283-induced inhibition of GSC invasion and migration 26 , as previously shown by others 37 .
In addition, the area occupied by mitochondria per cell was reduced in TAT-Cx43266-283-treated GSCs (Fig. 2c ). To establish if this result is due to the spatial rearrangement of mitochondria or to a decrease in mitochondrial mass, we performed western blotting against subunit proteins from each of the five complexes of the electron transport chain (ETC) involved in oxidative phosphorylation (OXPHOS). Treatment with TAT-Cx43266-283 did not affect the relative abundance of ETC complexes in GSCs ( Fig. 2d and Supplementary Fig.   2b ). Similarly, quantification of mitochondrial DNA relative to nuclear DNA by realtime quantitative polymerase chain reaction (qPCR) did not reveal any changes ( Fig. 2e and Supplementary Fig. 2c ), confirming that 24-h TAT-Cx43266-283 treatment induced a spatial rearrangement in the mitochondrial network of GSCs without changes in total mitochondrial mass. To further characterize the effect of TAT-Cx43266-283 on GSC mitochondria, we performed transmission electron microscopy. The images revealed that, in mitochondria from TAT-Cx43266-283treated GSCs, the matrix was more electron-dense and the outer membrane and cristae less defined, indicative of structural changes associated with the previous observations ( Fig. 2f ; the blue arrowheads indicate the outer membrane, the cristae are coloured).
To determine if the distinct cellular localization and ultrastructure observed in mitochondria from GSCs treated with TAT-Cx43266-283 affected mitochondrial function, we measured GSC oxygen consumption rate (OCR) as an indicator of mitochondrial respiration in a Seahorse XF Analyzer 38 . As shown in Fig. 2g , GSCs treated with TAT-Cx43266-283 had a lower basal OCR (minutes 0-18), as well as a lower response to mitochondrial stimulation with FCCP (minutes 42-55). Mitochondrial parameters 38 calculated from these data revealed that TAT-Cx43266-283 decreased basal respiration and ATP-linked respiration, as well as maximal and spare respiratory capacities ( Fig. 2h ). Phosphorylation of ETC complexes by c-Src regulates respiration and cellular ATP content 39 , which provides a mechanistic explanation for the decreased mitochondrial activity induced by TAT-Cx43266-283-a c-Src-inhibiting peptide 7,26 -, despite unchanged total levels of ETC complexes. Importantly, analysis of GSC glycolysis (Seahorse XF Analyzer 38 ) after TAT-Cx43266-283 treatment did not reveal any changes in the extracellular acidification rate (ECAR; mostly resulting from lactate production) ( Fig. 2i and Supplementary Fig. 2d ). We confirmed this result by analysing extracellular lactate in GSCs after TAT-Cx43266-283 treatment (Fig. 2j ). Recent reports show that drug resistance to standard therapies, such as bevacizumab, relies on the ability of cancer cells to switch their metabolism from OXPHOS to glycolysis 8 . Therefore, it is noteworthy that, despite the well-characterized ability of cancer stem cells to adapt to new metabolic requirements 10, 13, 14 , GSCs treated with TAT-Cx43266-283 did not show enhanced glycolysis to compensate for the decreased mitochondrial activity ( Fig. 2g vs 2i ). In addition, we did not find any significant effect on OCR or ECAR in neurons or astrocytes treated with TAT-Cx43266-283 ( Supplementary Fig. 2e ), in agreement with the cell-specific effect of TAT-Cx43266-283 6 . Taken together, these data indicate that TAT-Cx43266-283 specifically downregulates mitochondrial metabolism in GSCs without increasing aerobic glycolysis, which suggests an impairment of metabolic plasticity upon TAT-CX43266-283 treatment.
TAT-Cx43266-283 impairs the metabolic plasticity of GSCs
The plasticity of the metabolic phenotype of cancer stem cells is crucial in the ever-changing tumour microenvironment 8, 11, 13, 14 . In order to characterize the ability of the GSCs used in this study to adapt their metabolism to shifts in nutrient availability, we used time-lapse microscopy to analyse their survival in media with different nutrient contents. Interestingly, GSCs survived for 4 days with only glucose or only amino acids in the culture medium ( Fig. 3a , Supplementary Fig.   3a and Videos 1-2). Under these starvation conditions, GSCs eventually adopted a dormancy state, yet they were able to resume proliferation when nutrients became available once again ( Fig. 3a and videos 1.2 and 2.2), demonstrating a high metabolic plasticity.
Emerging data suggest that, beyond cell-intrinsic factors, nutrient availability in the tumour microenvironment can also influence drug response, hampering the efficacy of common antitumoral drugs 10 . To investigate whether this was also the case for TAT-Cx43266-283, GSCs in complete medium were treated with 50 μM At the molecular level, GSCs adapted to glucose-only medium by upregulating glucose metabolism enzymes critical for cancer cells, such as HK-2 11, 12 and glucose-6-phosphate-dehydrogenase (G6PD) 40, 41 , the key and ratelimiting enzyme in the pentose phosphate pathway ( Supplementary Fig. 3b ).
However, GSCs treated with TAT-Cx43266-283 in glucose-only medium showed markedly decreased levels of both HK-2 and G6PD, as well as GLUT-3, and, importantly, HIF-1ɑ, a master regulator of glucose metabolism 42, 43 (Fig. 3d ).
Meanwhile, HK-1 levels remained unchanged, suggesting that this is not a general reduction in glucose metabolism (Fig. 3d ). In addition, our results confirm that TAT-Cx43266-283 targets the metabolic adaptation to this nutrient-deprived condition because GSCs in complete medium showed no or only slight decreases in the levels of these proteins upon treatment with TAT-Cx43266-283 for 24 h or 48 h, respectively ( Fig. 1e and Fig. 3d ). On a different note, Sox-2, a transcription factor implicated in stem cell maintenance 7 , was also up-regulated in GSCs cultured in glucose-only medium ( Supplementary Fig. 3b ). This is in agreement with previous studies showing cancer stem cell enrichment under nutrientdeprived conditions and the role of certain master stem cell transcription factors in promoting preferential glucose metabolism 13, 44 . According to our previous results 7 , Sox-2 levels in treated GSCs were decreased in complete medium ( Fig.   3d ). Interestingly, here we found that this reduction also takes place in glucoseonly medium, suggesting TAT-Cx43266-283 abrogates GSC enrichment under this condition ( Fig. 3d ). Together, these results indicate that GSCs treated with TAT-Cx43266-283 fail to upregulate proteins necessary for survival in different metabolic scenarios, particularly those needed to exploit glucose as an energy source in the absence of other nutrients (e.g., amino acids/proteins or lipids) ( Fig. 3d and Supplementary Fig. 3b ). This lack of adaptation might be responsible for maintaining the effect of TAT-Cx43266-283 in different metabolic environments, in contrast to other antitumour therapies 8, 10 .
TAT-Cx43266-283 impairs glucose metabolism ex vivo and in vivo.
To explore the effect of TAT-Cx43266-283 on glucose metabolism in GSCs within the brain environment, we first evaluated glucose uptake in an ex vivo model of glioma 6 . As illustrated in Fig. 4a , fluorescently labelled GSCs were placed in organotypic brain slices and allowed to engraft overnight. The GSCorganotypic brain slice co-cultures were treated with 50 μM TAT or TAT-Cx43266-283 for 48 h, incubated with 146 μM 2-NBDG in glucose-free medium for 1 h and mounted for microscopy ( Fig. 4a and Supplementary Fig. 4a ). In agreement with the in vitro 2-NBDG study ( Fig. 1e and f), glucose uptake was reduced to ~65% in GSCs in co-cultures treated with TAT-Cx43266-283 compared with the control and TAT conditions ( Fig. 4b and c), with no apparent effect on the brain parenchyma ( Fig. 4c and Supplementary Fig. 4a ).
Next, we used an in vivo glioma model consisting of the intracranial injection of 5,000 fluorescently labelled human GSCs together with 100 μM TAT or TAT-Cx43266-283 into the brains of NOD/SCID mice 6 . Seven days after surgery, the mice were sacrificed, and their brains were processed for analysis ( Fig. 4d ). We had already found that TAT-Cx43266-283 in vitro impaired HK activity after 24 h of treatment ( Fig. 1g ) and decreased HK-2 levels after 48 h of treatment in glucoseonly medium (Fig. 3d ). We corroborated these findings in vivo through immunofluorescence analysis of HK-2 in the GSCs of the xenografted mice, who showed a ~75% reduction in HK-2 staining in GSCs injected with TAT-Cx43266-283 ( Fig. 4e and f and Supplementary Fig. 4b and d ).
Within the bulk glioma, GLUT-3 is preferentially expressed by GSCs in vivo and its inhibition impairs GSC growth and tumorigenicity, emerging as an important target in malignant gliomas 13 . Because our in vitro results showed a decreased level of GLUT-3 in glucose-only medium (Fig. 3d) , we analysed its level in the in vivo implanted GSCs as well. Notably, immunofluorescence analysis revealed a ~75% reduction in GLUT-3 staining in GSCs injected with TAT-Cx43266-283 ( Fig. 4g and h and Supplementary Fig. 4c and e ). This finding and the reduced HK-2 levels in GSCs in vivo recapitulate the HK-2 and GLUT-3 decrease found in GSC treated in glucose-only medium in vitro ( Fig. 3d ).
Discussion
Our previous studies showed that GSCs can be specifically targeted by a short cell-penetrating peptide based on Cx43 (TAT-Cx43266-283) that reduces tumour growth in preclinical models 6 via c-Src inhibition 7 . The effects of TAT-Cx43266-283 on GSC metabolism found in this study highlight the therapeutic potential of this compound against glioblastoma because TAT-Cx43266-283 targets crucial proteins for glioma malignancy, namely GLUT-3, HK-2, G6PD and HIF-1ɑ [11] [12] [13] [40] [41] [42] . Our in vitro, ex vivo and in vivo data show that glucose uptake is specifically impaired in GSCs through short-and long-term mechanisms involving the regulation of the activity and expression of key glucose enzymes. Indeed, our results suggest an initial short-term regulation of HK activity, presumably through the inhibition of its phosphorylation by c-Src 12 . This is followed by long-term regulation through reduced HK-2 protein levels, which is highly relevant considering the strong link between HK activity, particularly that of HK-2, and the malignant phenotype 11, 12 . We hypothesize that, because c-Src activity stabilizes the levels of HIF-1ɑ 29, 30 , TAT-Cx43266-283 might decrease HIF-1ɑ through c-Src inhibition, leading to the downstream downregulation of HK-2, G6PD and GLUT-3 shown here. In agreement with these results, Cx43 has been proposed to regulate glucose uptake, HK-2 and GLUT-3 through c-Src and HIF-1ɑ 29 . In addition, TAT-Cx43266-283 increases the levels of PTEN 26 , which could also contribute to blocking HIF-1ɑ-dependent gene transcription 45 .
GLUT-3 has been pinpointed as an excellent target to reduce glioma progression because of the high GSC dependence on this glucose transporter 13 .
However, in the brain context, the inhibition of GLUT-3 is challenging because it is also the main glucose transporter in neurons 46 . Remarkably, we found that TAT-Cx43266-283 downregulates GLUT-3 in GSCs without affecting glucose uptake in neurons, probably because its regulation in neurons is independent of c-Src activity 46 . In fact, TAT-Cx43266-283 appears to be innocuous in terms of neuron and astrocyte metabolism, presumably because of the low basal activity of c-Src in healthy cells 7 .
It has been reported that GSCs use OXPHOS as their primary energy source, for which they require an intact mitochondrial respiratory chain to survive and sustain their tumorigenic potential 47 . As previously mentioned, c-Src, via phosphorylation of ETC complexes, regulates mitochondrial respiration necessary for the survival of glioma cells 39 . Consistent with these reports, here we show that the c-Src inhibiting peptide, TAT-Cx43266-283, impairs glucose mitochondrial metabolism and promotes GSC death. Moreover, ATP generated in the ETC is necessary for the c-Src-activating phosphorylation at Y416 48 , which might create a negative regulatory loop when ATP becomes scarce due to TAT-Cx43266-283 treatment. In terms of glioma therapy, the impairment of mitochondrial metabolism is highly relevant because it might per se increase the effectiveness of radiotherapy 4 . Importantly, the reduced mitochondrial activity promoted by TAT-Cx43266-283 is not compensated by an increase in glycolysis, which is critical to avoid drug resistance [8] [9] [10] . Indeed, TAT-Cx43266-283 exerts antitumour effects in different nutrient-depleted media, where it prevents metabolic plasticity and eventually leads to cell death. This is especially relevant considering the growing body of work acknowledging intrinsic and extrinsic metabolic states as key factors in cancer drug resistance 8, 10, 32, 49 .
Although further research is needed to address the role of TAT-Cx43266-283 in amino acid, lipid and protein metabolism, our in vivo work shows that the effects of TAT-Cx43266-283 on GSC metabolism extend beyond in vitro conditions, indicating that they are independent of the metabolic tumour microenvironment, contrary to other antitumoral drugs 10 . The metabolically challenging tumour environment promotes GSC enrichment 13, 15, 16 , however, TAT-Cx43266-283 reduces GLUT-3 and HK-2 levels in GSCs in vivo, two proteins involved in glioma establishment, maintenance and resistance [11] [12] [13] . Concomitantly, in the same glioma model used in this study, TAT-Cx43266-283 induces the loss of the stemness phenotype of the implanted GSCs, as evidenced by decreased expression of Sox-2 and nestin in these cells 7 days post-implantation, and impairs glioma growth 30 days post-implantation, leading to decreased tumorigenicity and increased survival 6 . Given our in vitro, ex vivo and in vivo results and the fundamental role played by HK-2 11, 12 and GLUT-3 13 in glioma formation and development, TAT-Cx43266-283 might impair in vivo glioma growth through both the loss of the stemness phenotype 6 and the abrogation of metabolic plasticity, two phenomena that are highly dynamic and tightly linked 5, [13] [14] [15] [16] .
From a clinal point of view, the search for therapeutic molecules that specifically target the metabolism of cancer stem cells is on the rise 50 , with metabolic plasticity and nutrient composition of the tumour microenvironment at the centre of drug response 10 . Taken together, these results support the notion that metabolic plasticity, rather than specific metabolic pathways, constitutes a major targetable vulnerability 14 , and confirm the value of TAT-Cx43266-283 for glioma therapy alone or in combination with therapies whose resistance relies on metabolic adaptation. Cell cultures. G166 human GSCs (IDH-wt) 51 were obtained from BioRep and cultured as previously described 7 . The cells were cultured in RHB-A medium (Takara Bio Inc., Condalab) supplemented with 2% B27 (Life Technologies), 1% N2 (Life Technologies), 20 ng ml -1 EGF and 20 ng ml -1 b-FGF (PeproTech) under adherent conditions, as described by Pollard et al. 52 (complete medium). Culture plates were coated with 10 μg ml -1 laminin (Invitrogen, 23017-015) for 2 h before use. Cells were grown to confluence, dissociated using Accutase (Thermo Fisher) and then split to convenience. We routinely used cultures expanded for no more than 15 passages.
Primary rat neuron and astrocyte cultures were carried out as previously described 53 . Neurons in primary culture were prepared from the forebrains of foetuses at 17.5 days of gestation and cultured in Dulbecco's modified Eagle's medium (DMEM; Sigma-Aldrich, D5523) supplemented with 10% foetal calf serum (FCS; Gibco). One day after plating, cytosine arabinoside was added to avoid glial cell proliferation. Astrocytes in primary culture were prepared from the forebrains of 1-to 2-day-old Wistar rats and cultured in DMEM supplemented with 10% FCS. The cells were maintained at 37 °C in an atmosphere of 95% air/5% CO2 and with 90-95% humidity.
GSC-organotypic brain slice co-cultures. Organotypic brain slice cultures were prepared as previously described 54 . Briefly, 350-μm-thick brain slices were obtained from neonatal Wistar rats and cultured onto cell culture inserts in DMEM supplemented with 10% horse serum and glucose (final concentration, 33 mM).
The medium was replaced three times a week and slices were maintained in culture for 19-20 DIV. Then, 2,500 G166 GSCs fluorescently labelled with CellTracker Red CMPTX (Life Technologies) were placed onto each brain slice and maintained in culture for the indicated time.
Cell treatments. Synthetic peptides (> 85% pure) were obtained from GenScript (Piscataway, NJ, USA). YGRKKRRQRRR was used as the TAT sequence, which enables the cell penetration of the peptides 55 . The TAT-Cx43266-283 sequence was TAT-AYFNGCSSPTAPLSPMSP (patent ID: WO2014191608A1). Hexokinase activity assay. The HK activity of cells was determined using a commercial kit (Abcam, ab136957) following the manufacturer's instructions.
Results were normalized to the protein content of the samples. Supplementary Fig. 2 ).
Real
Real-time PCR results were analysed as described by Pfaffl et al. 58 Western blotting. Western blotting was performed as described previously 26 .
Briefly, equal amounts of proteins across conditions were separated on NuPAGE For the mitochondrial stress test, cells were plated in XF96 plates and treated with TAT or TAT-Cx43266-283 as indicated. Prior to the assay, the regular culture media was replaced with Base media (Seahorse Bioscience) supplemented with 1 mM pyruvate, 2 mM glutamine and 10 mM glucose and cells were incubated without CO2 for 1 h. Basal rate measurements were taken and then mitochondrial respiratory chain drugs were added, according to Mito Stress kit specifications. For glycolysis analysis, Base media supplemented with 0.5 mM pyruvate and 2 mM glutamine was used and cells were incubated without CO2 for 1 h. In accordance with Glycolysis Stress kit specifications, 10 mM glucose was injected to stimulate glycolysis, 1.5 μM oligomycin was then injected to obtain the maximal glycolytic capacity upon oxygen consumption inhibition and finally 50 mM 2deoxy-D-glucose (2-DG) was used to shut down all glycolysis.
OCR and ECAR were measured three times after the injection of each drug.
At least six replicates per condition were performed in each experiment.
Parameter calculations were performed using the Seahorse XF Cell Mito Stress Test Report Generator provided by Seahorse Biosciences. Non-mitochondrial respiration is the minimum rate measurement after Rot/AA injection; basal respiration is oxygen consumption used to meet cellular ATP demand, calculated by subtracting non-mitochondrial OCR from the measurement prior to oligomycin addition; proton leak is calculated by subtracting non-mitochondrial OCR from the minimum rate measurement after oligomycin injection; ATP-linked respiration is calculated by subtracting the minimum rate measurement after oligomycin injection from the last rate measurement before oligomycin injection; maximal respiration capacity is calculated by subtracting non-mitochondrial respiration from the maximum rate measurement after FCCP injection; and spare respiratory capacity, the capability to respond to an energetic demand, is calculated as the difference between maximal and basal respiration. Non-glycolytic acidification is the last rate measurement prior to glucose injection, glycolysis is calculated as the maximum rate measurement before oligomycin injection minus the last rate measurement before glucose injection, glycolytic capacity is calculated as the maximum rate measurement after oligomycin injection minus the last rate measurement before glucose injection and glycolytic reserve is calculated as glycolytic capacity minus glycolysis.
Extracellular lactate. Extracellular lactate was determined using a commercial kit (Sigma-Aldrich, mak064) and the cell media was filtered through 10,000 MTT assay. Cells cultured at 37 °C in 12-well plates were incubated in the dark for 75 min with culture medium containing 0.5 mg ml -1 MTT (Sigma-Aldrich). The cells were then carefully washed with PBS once and incubated for 10 min in the dark in dimethyl sulfoxide with mild shaking. Absorbance was measured at a wavelength of 570 nm using a microplate reader.
Ex vivo 2-NBDG uptake assay. GSC-organotypic brain slice co-cultures were incubated overnight to ensure GSC engraftment into the brain slices. The coculture brain slices were then incubated with 50 μM TAT or TAT-CX43266-283 for 48 h. On the day of the assay, the brain slices were incubated for 30 min in 2, respectively). After 4 days, these media were changed to complete medium and cells were recorded for a further 24 h (nutrient replenishment). Note that cells that appeared dead (bright, round shape) could survive and proliferate after nutrient replenishment, which was not true for cells maintained in medium with no nutrients at all ( Supplementary Fig. 3 (d) Representative western blots of the indicated proteins under the indicated conditions. GSCs treated with TAT-Cx43266-283 in glucose-only medium exhibit
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